(Q33671491)

28 July 2017

title

Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4. (English)

1 reference

28 July 2017

Rheum palmatum

1 reference

Zhaokai Wang

1 reference

28 July 2017

Longhe Yang

1 reference

28 July 2017

Hu Fan

1 reference

28 July 2017

Peng Wu

1 reference

28 July 2017

Fang Zhang

1 reference

28 July 2017

Chao Zhang

1 reference

28 July 2017

Wenjie Liu

1 reference

28 July 2017

Min Li

1 reference

28 July 2017

publication date

10 May 2017

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

e3283

1 reference

Creative Commons Attribution 4.0 International

28 July 2017

start time

10 May 2017

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Emodin regulates glucose utilization by activating AMP-activated protein kinase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Diabetes is an inflammatory disease: evidence from traditional Chinese medicines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Biology of incretins: GLP-1 and GIP

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Chinese herbal medicines for type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Immune reponses in human mesangial cells regulated by emodin from Polygonum hypoleucum Ohwi

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Emodin ameliorates high glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo.

21 June 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

The protection of Rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

Anti-diabetic effect of a traditional Chinese medicine formula.

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

Aloe emodin suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channels in dyslipidaemic-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.7717%2FPEERJ.3283

NTP Toxicology and Carcinogenesis Studies of EMODIN (CAS NO. 518-82-1) Feed Studies in F344/N Rats and B6C3F1 Mice.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5428354

Bioassay-guided isolation of DPP-4 inhibitory fractions from extracts of submerged cultured of Inonotus obliquus

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28507818

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3β signaling pathway in the rat model

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28507818

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28507818

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.7717/PEERJ.3283

1 reference

28 July 2017

1 reference

28 July 2017

1 reference